Compare CZWI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZWI | CCCC |
|---|---|---|
| Founded | 1938 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.7M | 185.1M |
| IPO Year | 2006 | 2020 |
| Metric | CZWI | CCCC |
|---|---|---|
| Price | $17.56 | $3.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 48.1K | ★ 2.2M |
| Earning Date | 04-27-2026 | 05-25-2026 |
| Dividend Yield | ★ 2.35% | N/A |
| EPS Growth | 8.96 | ★ 16.45 |
| EPS | ★ 1.46 | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | $13.02 | N/A |
| Revenue Next Year | $9.42 | N/A |
| P/E Ratio | $17.53 | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $12.69 | $1.09 |
| 52 Week High | $19.11 | $3.64 |
| Indicator | CZWI | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 41.00 | 69.53 |
| Support Level | $17.44 | $1.96 |
| Resistance Level | $18.90 | $3.07 |
| Average True Range (ATR) | 0.56 | 0.29 |
| MACD | -0.08 | 0.09 |
| Stochastic Oscillator | 19.05 | 87.76 |
Citizens Community Bancorp Inc is a bank holding company that offers traditional community banking services to businesses, Agricultural operators, and consumers, including one-to-four-family residential mortgages. it also offers a variety of loan products including commercial real estate loans, commercial and industrial (C&I) loans, agricultural real estate loans, agricultural operating loans, residential mortgages, home equity lines-of-credit, and consumer loans and offers deposit products through its branches, including demand deposits, various savings and money-market accounts and certificates of deposit. The company's sources of funds are deposits; amortization, prepayments, and maturities of outstanding loans; other short- term investments; and funds provided from operations.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.